Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | POLQ | O75417 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7245512 | 0.88 | HDAC4 (0.69) | HDAC4MEN1KMT2APGRGPBAR1 | |
| SCHEMBL5165280 | 0.86 | HDAC4 (0.58) | HDAC4MEN1KMT2APGRGPBAR1 | |
| SCHEMBL7003632 | 0.85 | HDAC4 (0.68) | HDAC4MEN1KMT2APGRGPBAR1 | |
| SCHEMBL5166744 | 0.85 | HDAC4 (0.57) | HDAC4MEN1KMT2APGRGPBAR1 | |
| SCHEMBL7623491 | 0.82 | HDAC4 (0.54) | HDAC4MEN1KMT2APGRGPBAR1 | |
| SCHEMBL7002185 | 0.82 | HDAC4 (0.76) | HDAC4MEN1KMT2APGRGPBAR1 | |
| SCHEMBL7721592 | 0.82 | MEN1 (0.46) | HDAC4MEN1KMT2APGRGPBAR1 | |
| SCHEMBL7717984 | 0.81 | HDAC4 (0.53) | HDAC4MEN1KMT2APGRGPBAR1 | |
| SCHEMBL7558495 | 0.81 | HDAC4 (0.53) | HDAC4MEN1KMT2APGRGPBAR1 | |
| SCHEMBL14376051 | 0.81 | HDAC4 (0.78) | HDAC4MEN1KMT2APGRGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1095021-B1 | QUINOLINE DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2003-09-17 | — | — | EP | disclosed |
| US-6593343-B2 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020173519-A1 | Quinoline derivatives | ACTIVE BIOTECH AB (SE) | 2002-11-21 | — | — | US | disclosed |
| US-6133285-A | 1-METHYL-2-OXO-3-N-PHENYL-N-METHYLAMINOCARBONYL-4-HYDROXY-1,2 -DIHYDRO-QUINOLINES; AUTOIMMUNE DISEASE AND PATHOLOGICAL INFLAMMATION, E.G., ASTHMA, ATHEROSCLEROSIS, STROKE AND ALZHEIMER'S DISEASE AND, ESPECIALLY, MULTIPLE SCLEROSIS | ACTIVE BIOTECH AB (SE) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173519-A1 | Quinoline derivatives | CASP1, NFKBIA, IL1B | HDAC4 1771/4885MEN1 1499/4885KMT2A 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.